Index RUT P/E - EPS (ttm) -2.01 Insider Own 39.25% Shs Outstand 49.18M Perf Week -8.76%
Market Cap 367.62M Forward P/E - EPS next Y -1.62 Insider Trans 21.99% Shs Float 42.86M Perf Month -3.16%
Income -107.91M PEG - EPS next Q -0.36 Inst Own 64.49% Short Float 19.48% Perf Quarter -5.27%
Sales 0.00M P/S - EPS this Y 33.41% Inst Trans -4.90% Short Ratio 11.97 Perf Half Y -59.86%
Book/sh 6.42 P/B 0.81 EPS next Y -1.27% ROA -21.95% Short Interest 8.35M Perf Year 208.28%
Cash/sh 4.60 P/C 1.13 EPS next 5Y - ROE -27.99% 52W Range 1.28 - 16.24 Perf YTD -21.06%
Dividend Est. - P/FCF - EPS past 5Y -209.81% ROI -20.24% 52W High -67.92% Beta 0.82
Dividend TTM - Quick Ratio 15.91 Sales past 5Y -39.65% Gross Margin - 52W Low 307.03% ATR (14) 0.47
Dividend Ex-Date - Current Ratio 15.91 EPS Y/Y TTM 21.46% Oper. Margin 0.00% RSI (14) 44.23 Volatility 7.75% 8.11%
Employees 150 Debt/Eq 0.19 Sales Y/Y TTM - Profit Margin - Recom 1.00 Target Price 17.80
Option/Short Yes / Yes LT Debt/Eq 0.18 EPS Q/Q 49.96% Payout - Rel Volume 1.02 Prev Close 5.38
Sales Surprise - EPS Surprise 27.94% Sales Q/Q - Earnings Aug 13 AMC Avg Volume 697.68K Price 5.21
SMA20 -5.85% SMA50 -10.90% SMA200 -29.67% Trades
Volume 712,774 Change -3.16%
Date
Action
Analyst
Rating Change
Price Target Change
Aug-14-24 Upgrade Raymond James
Outperform → Strong Buy
$16
Mar-22-24 Downgrade Raymond James
Strong Buy → Outperform
$13 → $16
Dec-22-22 Downgrade Oppenheimer
Outperform → Perform
Oct-10-22 Initiated Canaccord Genuity
Buy
$25
Jul-28-22 Initiated Needham
Buy
$26
Jul-18-22 Initiated SVB Leerink
Outperform
$30
Mar-11-22 Initiated Raymond James
Outperform
$17
Mar-08-22 Initiated H.C. Wainwright
Buy
$25
Jan-06-22 Initiated William Blair
Outperform
Nov-18-21 Initiated SMBC Nikko
Outperform
$50
Jul-16-21 Initiated Oppenheimer
Outperform
$75
Aug-04-20 Initiated Stifel
Buy
$41
Aug-04-20 Initiated Mizuho
Buy
$34
Aug-04-20 Initiated Evercore ISI
Outperform
$55
Aug-04-20 Initiated Cowen
Outperform
Show Previous Ratings
Sep-03-24 04:01PM
Aug-14-24 12:37PM
Aug-13-24 09:03PM
04:01PM
Jul-24-24 06:00AM
06:01AM
Loading…
Jul-16-24 06:01AM
Jul-10-24 12:00PM
Jul-01-24 10:20AM
Jun-27-24 06:00AM
Jun-13-24 04:01PM
May-10-24 02:56PM
May-09-24 10:57PM
04:01PM
May-07-24 06:30AM
Apr-03-24 04:02PM
04:06PM
Loading…
Mar-25-24 04:06PM
(Investor's Business Daily) +17.60%
-5.91%
06:30AM
Mar-23-24 05:31AM
Mar-22-24 04:03PM
(Investor's Business Daily) -31.28%
+17.60%
09:18AM
Mar-21-24 10:54PM
04:01PM
Mar-19-24 07:29AM
Feb-29-24 06:30AM
Feb-28-24 08:01AM
Feb-20-24 04:19PM
Feb-08-24 09:32AM
Feb-06-24 12:50PM
Feb-05-24 12:41PM
Feb-04-24 08:00AM
10:25AM
Loading…
Jan-09-24 10:25AM
Dec-09-23 08:31PM
Dec-08-23 12:00PM
Nov-14-23 03:56PM
Nov-09-23 04:02PM
11:38AM
Nov-07-23 08:02AM
Oct-25-23 02:06PM
Oct-18-23 10:47AM
01:18AM
Oct-17-23 08:17PM
(FierceBiotech.com) +112.16%
11:47AM
07:01AM
Oct-16-23 04:01PM
Oct-02-23 03:07PM
Aug-10-23 07:01AM
Aug-03-23 08:02AM
Jul-31-23 06:30PM
Jul-05-23 04:02PM
Jun-28-23 09:35AM
Jun-27-23 01:02PM
07:01AM
Jun-26-23 04:01PM
Jun-15-23 09:55AM
Jun-10-23 10:47AM
May-11-23 04:02PM
04:01PM
May-09-23 07:15AM
May-07-23 12:50PM
Apr-17-23 05:01PM
Apr-12-23 09:06PM
Apr-11-23 09:46AM
Mar-30-23 04:01PM
Mar-16-23 04:01PM
Feb-17-23 05:35AM
Feb-09-23 08:02AM
Jan-09-23 04:30PM
Dec-05-22 07:02AM
Dec-02-22 04:02PM
Nov-09-22 04:02PM
Nov-07-22 08:52AM
Nov-02-22 08:02AM
Sep-24-22 09:34AM
Sep-23-22 07:30AM
Aug-11-22 04:02PM
Aug-10-22 08:42AM
Aug-07-22 06:15AM
Jul-25-22 04:31PM
Jul-18-22 02:46PM
Jun-14-22 07:14AM
Jun-07-22 09:55AM
May-31-22 07:02AM
May-18-22 12:00PM
09:55AM
May-16-22 04:02PM
May-12-22 04:02PM
May-09-22 04:02PM
May-06-22 05:30PM
May-02-22 10:45AM
Apr-28-22 04:01PM
10:18AM
Apr-25-22 11:19PM
(GlobeNewswire) +140.93%
-10.31%
06:04PM
05:44PM
(American City Business Journals)
04:09PM
(Investor's Business Daily)
04:01PM
03:52PM
10:49AM
08:34AM
08:19AM
Nkarta, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of natural killer cell therapies for the treatment of cancer. The firm's product include NKX101, which is in Phase I clinical trials for the treatment of relapsed/refractory acute myeloid leukemia or higher risk myelodysplastic syndromes, and NKX019, a pre-clinical product, which is based on the ability to treat various B cell malignancies by targeting the CD19 antigen found on these types of cancerous cells. The company was founded by Dario Campana in 2005 and is headquartered in South San Francisco, CA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Hager Alicia J. Chief Legal Officer Jul 16 '24 Sale 8.00 3,396 27,168 103,819 Jul 18 04:22 PM Trager James Chief Scientific Officer Jun 18 '24 Sale 5.60 456 2,554 150,959 Jun 20 05:04 PM HASTINGS PAUL J Chief Executive Officer Jun 18 '24 Sale 5.60 1,770 9,912 240,737 Jun 20 05:03 PM Shook David Chief Medical Officer Jun 18 '24 Sale 5.60 456 2,554 116,524 Jun 20 05:03 PM Hager Alicia J. Chief Legal Officer Jun 18 '24 Sale 5.60 727 4,071 107,215 Jun 20 05:02 PM Brandenberger Ralph Chief Technical Officer Jun 18 '24 Sale 5.60 229 1,282 79,743 Jun 20 05:01 PM RA CAPITAL MANAGEMENT, L.P. Director Mar 27 '24 Buy 10.00 3,000,000 30,000,000 10,050,818 Mar 29 05:38 PM George Simeon Director Mar 27 '24 Buy 10.00 2,000,000 20,000,000 1,548,341 Mar 28 04:30 PM Brandenberger Ralph Chief Technical Officer Mar 01 '24 Option Exercise 3.89 6,763 26,308 88,339 Mar 05 04:26 PM Brandenberger Ralph Chief Technical Officer Mar 01 '24 Sale 12.51 8,367 104,671 79,972 Mar 05 04:26 PM Trager James Chief Scientific Officer Feb 12 '24 Sale 12.00 4,143 49,716 149,415 Feb 14 09:12 PM Shook David Chief Medical Officer Jan 16 '24 Sale 8.74 3,552 31,044 114,980 Jan 18 04:45 PM Trager James Chief Scientific Officer Jan 16 '24 Sale 8.74 4,560 39,854 153,558 Jan 18 04:43 PM Brandenberger Ralph Chief Technical Officer Jan 16 '24 Sale 8.74 2,512 21,955 81,576 Jan 18 04:40 PM HASTINGS PAUL J Chief Executive Officer Jan 16 '24 Sale 8.74 9,697 84,752 390,507 Jan 18 04:40 PM Hager Alicia J. Chief Legal Officer Jan 16 '24 Sale 8.74 4,554 39,802 107,942 Jan 18 04:38 PM
Index RUT P/E - EPS (ttm) -0.90 Insider Own 43.30% Shs Outstand 56.47M Perf Week 6.14%
Market Cap 332.93M Forward P/E - EPS next Y -1.17 Insider Trans -3.11% Shs Float 32.10M Perf Month 12.00%
Income -50.53M PEG - EPS next Q -0.24 Inst Own 41.68% Short Float 6.83% Perf Quarter 73.96%
Sales 0.00M P/S - EPS this Y 23.25% Inst Trans 3.10% Short Ratio 8.34 Perf Half Y 80.37%
Book/sh 4.61 P/B 1.27 EPS next Y -28.47% ROA -17.39% Short Interest 2.19M Perf Year 139.02%
Cash/sh 4.61 P/C 1.28 EPS next 5Y - ROE -18.11% 52W Range 1.96 - 6.91 Perf YTD 121.89%
Dividend Est. - P/FCF - EPS past 5Y -138.68% ROI -19.20% 52W High -14.91% Beta 1.83
Dividend TTM - Quick Ratio 41.42 Sales past 5Y 0.00% Gross Margin - 52W Low 200.00% ATR (14) 0.47
Dividend Ex-Date - Current Ratio 41.42 EPS Y/Y TTM 32.44% Oper. Margin 0.00% RSI (14) 63.14 Volatility 6.23% 9.79%
Employees 124 Debt/Eq 0.01 Sales Y/Y TTM - Profit Margin - Recom 2.33 Target Price 7.00
Option/Short Yes / Yes LT Debt/Eq 0.01 EPS Q/Q 41.48% Payout - Rel Volume 2.17 Prev Close 5.86
Sales Surprise - EPS Surprise 9.99% Sales Q/Q - Earnings Aug 05 BMO Avg Volume 262.83K Price 5.88
SMA20 14.06% SMA50 22.93% SMA200 63.39% Trades
Volume 570,011 Change 0.34%
Date
Action
Analyst
Rating Change
Price Target Change
May-07-24 Upgrade Piper Sandler
Neutral → Overweight
$6 → $12
Nov-14-23 Downgrade Piper Sandler
Overweight → Neutral
$42 → $6
Aug-15-23 Downgrade Wedbush
Outperform → Neutral
$19 → $6
Aug-15-23 Downgrade SVB Securities
Outperform → Market Perform
$6
Aug-15-23 Downgrade RBC Capital Mkts
Outperform → Sector Perform
$23 → $7
May-04-23 Upgrade Goldman
Sell → Neutral
$6
Jun-10-22 Initiated Wedbush
Outperform
$21
May-02-22 Initiated RBC Capital Mkts
Outperform
$30
Jan-19-22 Initiated Goldman
Sell
$10
Apr-20-21 Initiated SVB Leerink
Outperform
$36
Apr-20-21 Initiated Piper Sandler
Overweight
$42
Apr-20-21 Initiated Goldman
Neutral
$28
Show Previous Ratings
Sep-10-24 08:00AM
Aug-21-24 09:55AM
Aug-05-24 08:00AM
May-22-24 08:50PM
May-10-24 03:36PM
11:55PM
Loading…
May-08-24 11:55PM
04:05PM
May-07-24 07:12AM
06:30AM
Mar-20-24 10:31AM
06:58AM
(Thomson Reuters StreetEvents)
Mar-19-24 08:53PM
05:33PM
04:01PM
Mar-12-24 06:30AM
12:00PM
Loading…
Dec-18-23 12:00PM
Nov-14-23 07:28PM
Nov-13-23 04:05PM
Aug-15-23 03:02PM
09:59AM
02:34AM
Aug-14-23 04:05PM
04:01PM
Jun-18-23 08:03AM
May-31-23 06:30AM
May-09-23 04:05PM
May-08-23 06:05AM
Apr-24-23 06:30AM
Apr-11-23 09:55AM
Apr-04-23 02:47PM
04:05PM
Loading…
Mar-14-23 04:05PM
Mar-09-23 06:33AM
Feb-08-23 06:30AM
Dec-21-22 06:46AM
Dec-14-22 05:15AM
Dec-07-22 04:01PM
(GlobeNewswire) -6.00%
-33.33%
Nov-28-22 10:37AM
Nov-03-22 04:05PM
Oct-17-22 04:05PM
Sep-22-22 06:30AM
Aug-08-22 04:05PM
Aug-03-22 06:30AM
Jun-21-22 09:57AM
Jun-01-22 06:30AM
May-09-22 04:05PM
Mar-30-22 06:30AM
Mar-23-22 02:53PM
Mar-10-22 04:02PM
Mar-09-22 06:30AM
Feb-28-22 04:05PM
Feb-10-22 06:30AM
Feb-01-22 04:05PM
Jan-19-22 12:51PM
Dec-23-21 05:00AM
Nov-09-21 04:05PM
Sep-24-21 07:55AM
Sep-08-21 06:30AM
Sep-03-21 07:33AM
Aug-09-21 04:05PM
Jun-26-21 04:30AM
Jun-07-21 04:10PM
04:05PM
May-10-21 04:05PM
Mar-30-21 04:05PM
Mar-25-21 11:56PM
Design Therapeutics, Inc. operates as a biotechnology company that develops therapies for serious degenerative disorders. It is created to design, develop and commercialize a novel class of small molecule therapeutic candidates (GeneTACs) designed to directly address the underlying basis of genetic disease. The company was founded by Pratik Shah and Aseem Z. Ansari on December 18, 2017 and is headquartered in Carlsbad, CA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
William Arsani Director Aug 09 '24 Sale 4.25 814,874 3,463,214 0 Aug 12 04:30 PM Logos SPV 1 LP Director Aug 09 '24 Proposed Sale 4.24 814,874 3,455,066 Aug 09 04:20 PM Schmid John P. Director Mar 25 '24 Buy 3.74 17,809 66,606 26,965 Mar 25 07:10 PM Schmid John P. Director Mar 22 '24 Buy 3.62 9,156 33,133 9,156 Mar 25 07:10 PM Berger Heather A. Director Mar 25 '24 Buy 3.74 1,300 4,866 1,300 Mar 25 07:09 PM LAPPE RODNEY W Director Sep 29 '23 Buy 2.35 21,000 49,287 133,024 Oct 02 06:01 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite
